Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06051695 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by A2 Biotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 474
- Enrollment target
- 12
- Study locations
NCT06051695 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by A2 Biotherapeutics. The registered enrollment target is 474 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (28% lower). The trial reports 12 study locations across 9 states.
The verdict
NCT06051695, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by A2 Biotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 474 participants
- Enrollment target
- 12
- Study locations
Study Summary
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose that is safe for patients Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and Apheresis in BASECAMP-1 (NCT04981119) Preconditioning Lymphodepletion (PCLD) Regimen Tmod CAR T cells at the assigned dose
Conditions Studied
Interventions
- BIOLOGICAL A2B694
- BIOLOGICAL A2B543
- DIAGNOSTIC_TEST xT CDx with HLA-LOH Assay
Study Locations (12)
California
- UCSD Moores Cancer Center - La Jolla
- UCLA Medical Center - Los Angeles
- Stanford University - Stanford
Florida
- Mayo Clinic - Jacksonville
- Moffitt Cancer Center - Tampa
Arizona
- Banner Health - Gilbert
Minnesota
- Mayo Clinic Rochester - Rochester
Missouri
- Washington University - St Louis
New York
- NYU Langone Medical Center - New York
Ohio
- The Ohio State University Comprehensive Cancer Center - Columbus
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2024-04-03 |
| Est. Completion | 2029-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06051695
The ClinicalTrials.gov registry entry for NCT06051695 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 474 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (28% lower). The listed sponsor is A2 Biotherapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which A2B694 is the first listed.
NCT06051695 reports 12 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06051695 about?
NCT06051695 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression". The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin...
What is the current status of trial NCT06051695?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 474 participants. The study started on 2024-04-03. Estimated completion is 2029-06.
What conditions does trial NCT06051695 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, NSCLC, Pancreas Cancer.
What interventions are being tested in trial NCT06051695?
The interventions under investigation include: A2B694 (BIOLOGICAL), A2B543 (BIOLOGICAL), xT CDx with HLA-LOH Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06051695?
This trial is sponsored by A2 Biotherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06051695 being conducted?
This trial has 12 study locations across Arizona, California, Florida, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.